Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
To read the full story
Related Article
- Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
February 5, 2021
- Chugai Enjoys Higher Earnings in January-September on Hemlibra
October 23, 2020
- Chugai’s Half-Year Earnings Surge on Actemra/Hemlibra Exports
July 28, 2020
- Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
- Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
January 31, 2020
- Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays
October 25, 2019
- Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
BUSINESS
- Takeda CEO Weber to Retire Next Year, Succeeded by US Head
January 30, 2025
- Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President
January 30, 2025
- Jazz Obtains Pharmaceutical Marketing License in Japan
January 30, 2025
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- ASKA, Susmed Initiate Clinical Study of PMS Therapeutic App
January 29, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…